Hemp Industry

Strategic partnership sees Canxchange enter medical cannabis market

Medical cannabis products can now be bought and sold via Canxchange’s electronic trading infrastructure.

Brains Bio receive FSA CBD validation
Home / Strategic partnership sees Canxchange enter medical cannabis market

Estimated reading time: 2 minutes

Physical cannabis exchange, Canxchange, has entered into a partnership with cannabis consultants EPC Healthcare Gmbh.

London-based Canxchange will begin adding global pharmaceutical companies and medical organisations to their member network with the help of EPC Healthcare. The partnership will uncover and highlight business opportunities for the field.  

Businesses in the sector will now have access to the technology and services needed to accelerate their procurement and supplier onboarding processes, while simultaneously benefitting from a secure payment solution and due diligence tools. 

Read more: Canxchange launches new trading system for the cannabis market

Canxchange CEO & co-founder, Alex Arkentis, commented: “Our entry into medical cannabis has been two years in the making and is an integral part of our strategy. The main objective of this launch is to encourage the production and distribution of medical cannabis globally. 

“Our strategic partner, EPC Healthcare  GmbH, has been invaluable in helping Canxchange enter the sector and gain access at the highest levels.”

EPC is represented by experienced pharma specialists Klaus-Jürgen Preuss and Martin Zentgraf. Both are medical doctors by education and have been active for many years in leading roles in the pharmaceutical and medical device industry, with a  specific focus on medical cannabis most recently.  

Preuss and Zentgraf commented: “Since the legalisation of medical cannabis in Germany, we have seen increasing demand for quality products year after year.  

Read more: Canxchange explores the global pricing of hemp

“This trend will continue as other countries are taking a more liberal stance and with the potential of legal recreational usage. The  discrepancy between availability of quality cannabis and demand will continue to grow in Europe and Canxchange is well-positioned to fill these gaps.”

The announcement comes following the company’s success in implementing a market infrastructure for hemp-derived transactions, where they will continue to operate and equally invest.  

[activecampaign form=31]

Topicscannabis industrycannabis marketshempmedical cannabis

Stephanie Price

Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained".

More from Stephanie

Spotted an error, or have a tip? Contact the newsroom.

Up next · Hemp Industry

Whole Hemp Plant Could Soon Be Recognised as Agricultural Crop in the EU, but States Will Keep Power to Criminalise

Ben Stevens · 29 October 2026

More